Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility

Keyphrases

• Human Immunodeficiency Virus Type 1 (HIV-1) 100%
• Reverse Transcriptase Inhibitors 100%
• Replication Capacity 100%
• Inhibitor Drug 100%
• Drug Resistance mutations 100%
• Phenotypic Susceptibility 100%
• Resistance mutations 75%
• Decreased Susceptibility 75%
• Reverse Transcriptase 75%
• Virus 50%
• Nucleoside Reverse Transcriptase Inhibitors 50%
• Genetic Resistance 50%
• Virus Strains 50%
• Increased Vulnerability 50%
• Zidovudine 50%
• Lamivudine 50%
• Stavudine 50%
• Tenofovir 50%
• Abacavir 50%
• M184V 50%
• Didanosine 50%
• Site-directed mutagenesis 25%
• HIV Patients 25%
• Quantitative PCR 25%
• Amino Acids 25%
• Clinical Practice 25%
• Drug Resistance 25%
• Recombinant Virus 25%
• HIV Viral Load 25%
• Resistance Phenotypes 25%
• Fixed-dose Combination 25%
• Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) 25%
• Recombinant Strain 25%
• Interaction Patterns 25%
• Nonnucleoside Reverse Transcriptase Inhibitor Resistance 25%
• K103N 25%
• Treatment-experienced Patients 25%
• Complex Resistance 25%
• Combination pill 25%

Pharmacology, Toxicology and Pharmaceutical Science

• RNA Directed DNA Polymerase Inhibitor 100%
• RNA Directed DNA Polymerase 100%
• Drug Resistance 100%
• Human Immunodeficiency Virus 1 100%
• HIV 50%
• Virus Strain 50%
• Tenofovir 50%
• Zidovudine 50%
• Nonnucleoside Reverse Transcriptase Inhibitor 50%
• Didanosine 50%
• Stavudine 50%
• Abacavir Plus Lamivudine 50%
• Amino Acid 25%
• Site-Directed Mutagenesis 25%

Immunology and Microbiology

• Human Immunodeficiency Virus 1 100%
• Drug Resistance 100%
• Reverse Transcriptase 100%
• Virus Strain 22%
• Tenofovir 22%
• Blood Plasma 11%
• Human Immunodeficiency Virus 11%
• Site Directed Mutagenesis 11%
• Recombinant Virus 11%
• Reverse Transcription Polymerase Chain Reaction 11%